Abstract | OBJECTIVE: METHODS: A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/ platinum regimens. The polymorphisms of MTHFR C677T, ERCC1 C8092A, and ERCC1 C118T were genotyped using the TaqMan methods. RESULTS: The overall response rate was 28.9%. Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype (TT or CT) (41.2% versus 19.1%, P=0.01). Median time to progression ( TTP) of patients with MTHFR CC genotype was longer than that of patients with variant genotype (7.6 months versus 5.0 months, P=0.003). No significant associations were obtained between ERCC1 C118T and C8092A polymorphisms and both response and survival. CONCLUSIONS: Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/ platinum.
|
Authors | Wei Hong, Kai Wang, Yi-ping Zhang, Jun-yan Kou, Dan Hong, Dan Su, Wei-min Mao, Xin-min Yu, Fa-jun Xie, Xiao-jian Wang |
Journal | Journal of Zhejiang University. Science. B
(J Zhejiang Univ Sci B)
Vol. 14
Issue 3
Pg. 207-15
(Mar 2013)
ISSN: 1862-1783 [Electronic] China |
PMID | 23463763
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Genetic Markers
- Deoxycytidine
- Methylenetetrahydrofolate Reductase (NADPH2)
- Gemcitabine
|
Topics |
- Adult
- Aged
- Antimetabolites, Antineoplastic
(therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, epidemiology, genetics)
- China
(epidemiology)
- Deoxycytidine
(analogs & derivatives, therapeutic use)
- Female
- Genetic Markers
(genetics)
- Genetic Predisposition to Disease
(epidemiology, genetics)
- Humans
- Lung Neoplasms
(drug therapy, epidemiology, genetics)
- Male
- Methylenetetrahydrofolate Reductase (NADPH2)
(genetics)
- Middle Aged
- Outcome Assessment, Health Care
(methods, statistics & numerical data)
- Polymorphism, Single Nucleotide
(genetics)
- Prevalence
- Reproducibility of Results
- Retrospective Studies
- Sensitivity and Specificity
- Treatment Outcome
- Gemcitabine
|